Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have been assigned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $32.25.

DTIL has been the subject of several analyst reports. JonesTrading reiterated a “buy” rating and issued a $30.00 price objective on shares of Precision BioSciences in a research note on Friday, April 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $19.00 price objective on shares of Precision BioSciences in a research note on Friday, March 13th. Oppenheimer initiated coverage on shares of Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price objective for the company. Weiss Ratings upgraded shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research note on Wednesday, May 27th.

Institutional Trading of Precision BioSciences

Several hedge funds and other institutional investors have recently bought and sold shares of DTIL. HBK Sorce Advisory LLC acquired a new stake in Precision BioSciences in the 4th quarter worth about $38,000. Engineers Gate Manager LP bought a new position in Precision BioSciences in the 4th quarter valued at about $43,000. Occudo Quantitative Strategies LP bought a new position in Precision BioSciences in the 4th quarter valued at about $52,000. Miller Financial Services LLC increased its holdings in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after buying an additional 5,000 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Precision BioSciences in the 3rd quarter valued at about $72,000. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Stock Performance

NASDAQ DTIL opened at $6.21 on Tuesday. The firm has a 50-day moving average of $7.05 and a 200-day moving average of $5.50. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The stock has a market cap of $160.22 million, a PE ratio of -1.69 and a beta of 1.30. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The business had revenue of $10.84 million during the quarter, compared to analyst estimates of $4.05 million. On average, sell-side analysts anticipate that Precision BioSciences will post -2.21 EPS for the current year.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.